The Center for OCD Research at Columbia University Irving Medical Center is seeking individuals with obsessive-compulsive disorder (OCD) to participate in a research study, at no cost to you. This study is investigating the medicinal effects of nabilone for OCD symptoms. Nabilone is a synthetic form of tetrahydrocannabinol (THC), which is one of the active…
Pain is a natural response to injury to let us know there may be damage to our bodies. Pain is the way our body tells us that we must take care of ourselves. Chronic pain is different and lasts for a long time. In some cases, chronic pain remains without any sign of body damage. Today, there is no way for a doctor to measure someone's chronic pain or…
The goal of the project is to identify differences in learning in obsessive-compulsive disorder (OCD) by measuring the activity of the brain while participants complete computer tasks. Eligible participants will be asked questions about their medical and psychiatric history and perform tasks on a computer while an electroencephalogram (EEG) is recorded.…
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
The Center for OCD and Related Disorders at New York State Psychiatric Institute/Columbia University Medical Center is seeking individuals aged 18+ with obsessive-compulsive disorder (OCD) to participate in a survey regarding their experiences with marijuana/cannabis. We hope this study will lead to increased understanding of how these substances affect…
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Eligible participants will be asked questions about their symptoms, complete questionnaires, and receive sessions of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP) accompanied by the use of a mobile app. The purpose of this study is to assess whether the mobile app may be effective in improving symptoms of OCD.
The purpose of this study is to assess the effects of a single infusion of ketamine for adolescents and young adults with obsessive-compulsive disorder (OCD). Ketamine is a FDA-approved anesthetic medication that can possibly cause a rapid decrease in OCD symptoms. To be eligible to participate, patients need to have already tried at least one SRI…
The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients enrolled in the study will smoke marijuana containing different concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on…
This study is investigating how the brains of people with OCD may change with treatment. The study uses Magnetic Resonance Imaging (MRI) to scan the brain, and the treatment used is a form of Cognitive-Behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP). Participants will undergo a scan, which lasts for approximately 2 hours and takes…
The study aims to assess the impact of repetitive transcranial magnetic stimulation (rTMS) on brain imaging and neurophysiological measures in patients with Obsessive-Compulsive Disorder (OCD).
The Center for OCD and Related Disorders is currently conducting a study in treating Obsessive-compulsive Disorder (OCD), which is a severe illness characterized by distressing intrusive thoughts, images, or impulses about a variety of themes (e.g., fears of contamination or harm) and repetitive behaviors such as excessive washing or checking. The study is…
SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated dose of SY-1365, and to assess the safety of SY-1365 in…
This is a Phase 1/2 multicenter study of VX15/2503 in pediatric patients and young adults with solid tumors which have come back or have not responded to standard therapy. The study treatment is considered experimental because VX15/2503 is not approved by the United States (US) Food and drug Administration (FDA) for treating pediatric patients and young…